You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
神州細胞(688520.SH):新冠疫苗SCTV01E國內III期臨牀研究顯示 針對奧密克戎及其各子變異株具有良好保護效力
格隆匯 05-12 19:40

格隆匯5月12日丨神州細胞(688520.SH)公佈,控股子公司神州細胞工程有限公司自主研發的重組新冠病毒4價(Alpha/Beta/Delta/Omicron變異株)S三聚體蛋白疫苗(項目代號: SCTV01E,商品名:安諾能®4)國內III期保護效力和安全性臨牀試驗已完成關鍵性數據最終分析並取得主要結果。

目前已完成本次III期臨牀研究的最終分析,研究結果顯示,在我國奧密克戎BA.5、BF.7和XBB等變異株流行期間,SCTV01E在≥18週歲已完成新冠疫苗基礎免疫或加強免疫人羣中進行1劑加強免疫後,產生了針對奧密克戎及其各子變異株的良好保護效力,且具有良好的安全性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account